NCT03962647View on ClinicalTrials.gov

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

March 7, 2024

Study Completion Date

July 14, 2024

Conditions
Estrogen Receptor-positive Breast Cancer
Interventions
DIETARY_SUPPLEMENT

2-Week Ketogenic Diet

2-Week Ketogenic Diet in Combination with Letrozole

DRUG

Letrozole

2.5 mg taken once daily by mouth

Trial Locations (1)

37232

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT03962647 - A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer | Biotech Hunter | Biotech Hunter